Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin.

ABSTRACT:

Background

Kidney transplant recipients are given induction therapy to rapidly reduce the immune response and prevent rejection. Guidelines recommend that an interleukin-2 receptor antibody (basiliximab) be the first-line agent and that a lymphocyte-depleting agent (antithymocyte globulin [ATG]) be reserved for those at high immunologic risk.

Objective

To determine the incidence, risk factors, and outcomes for patients who receive both basiliximab and ATG for induction compared to either agent alone.

Design

Retrospective cohort study.

Setting

We used the transplant electronic medical record at the University of Alberta Hospital in Edmonton, Canada.

Patients/samples/participants

We included incident adult kidney transplant recipients from 2013 to 2018.

SUBMITTER: Jeong R 

PROVIDER: S-EPMC7573718 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature